SFDA Experts Set To Determine Approval Of H1N1 Vaccine
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA scheduled final tests of an H1N1 flu vaccine that could mean immediate approval for release to the public. The vaccine has completed clinical trials, so the SFDA called in experts for a certification meeting with limited public and media opportunity to express concerns, but results could be determined by the end of the day. The agency is acting after a week that saw the number of H1N1 cases grew to near 3,398, although no deaths have been confirmed. (Click here for more
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.